Advanced therapies is the umbrella term encompassing an emerging category of therapeutics that has pushed the broader biopharma ecosystem into genuinely new scientific and regulatory territory — a category that now includes cell therapy, gene therapy, gene editing, mRNA-based therapeutics, and engineered bacteriophage, among other rapidly developing modalities.
How Does the Biopharma World Traditionally Categorize Therapeutics?
The biopharma world has historically segmented into two broad categories: small molecule and large molecule therapeutics. Small molecules are solid-state, typically orally administered medicines with a defined, reproducible chemical structure — common examples include widely used over-the-counter pain relievers. Large molecule therapeutics, more commonly called biologics, are typically administered through injection and include vaccines, monoclonal antibodies, and recombinant proteins — products derived from living cells rather than synthesized through traditional chemical processes.
Advanced therapies represent an emerging class within, and in some respects beyond, this large-molecule category — sharing biologics’ reliance on living systems for production, but introducing mechanisms of action, manufacturing requirements, and regulatory considerations distinct enough from traditional biologics to warrant their own classification.
What Modalities Fall Under the Advanced Therapies Umbrella?
The advanced therapies category was originally synonymous with cell and gene therapy specifically, but has expanded considerably as the underlying science has progressed. Cell therapies modify or introduce living cells to treat disease, with CAR-T representing the category’s most commercially mature example. Gene therapies introduce genetic material to treat or prevent disease by addressing its underlying genetic cause. Gene editing technologies, including CRISPR-Cas9, make precise, targeted modifications directly to a cell’s existing DNA. More recently, mRNA-based therapeutics and engineered bacteriophage have joined this broader category, each bringing distinct mechanisms while sharing the advanced therapies category’s defining characteristics: reliance on living or biologically derived systems, generally more complex manufacturing than traditional biologics, and regulatory frameworks still actively maturing alongside the underlying science.
Why Do Advanced Therapies Warrant Their Own Category Rather Than Falling Under Traditional Biologics?
Advanced therapies differ from traditional biologics in ways significant enough to justify distinct regulatory and commercial treatment. Manufacturing complexity is considerably higher across most advanced therapy modalities — autologous cell therapies require patient-specific manufacturing rather than standardized batch production serving a broad patient population, and gene therapies require specialized viral vector production infrastructure considerably more complex than the cell culture processes underlying most traditional biologics manufacturing.
The therapeutic mechanism itself also differs fundamentally: where traditional biologics typically supplement or block a specific biological pathway, many advanced therapies directly modify a patient’s own cells or genetic material, introducing a category of risk — including permanent genetic modification and long-term immunological consequences — that doesn’t have a direct precedent in traditional biologics development. This distinction is precisely why regulatory bodies have built dedicated frameworks, including the FDA’s Regenerative Medicine Advanced Therapy designation, specifically for this category rather than evaluating these products purely against standards built for conventional biologics.
How Quickly Has the Advanced Therapies Category Grown?
The advanced therapies category has expanded from a handful of approved products before 2017 to 24 approved therapies by 2024, with the pace of new approvals roughly tripling over that period and more than 2,100 active clinical trials currently underway globally across the category’s various modalities. This growth has extended well beyond the hematologic malignancies and rare monogenic diseases where advanced therapies first demonstrated commercial viability, into central nervous system disorders, metabolic disease, ophthalmology, neuromuscular conditions, and cardiovascular disease — therapeutic areas where advanced therapy programs are now active but, in most cases, have not yet reached approval.
How Has the Manufacturing Model for Advanced Therapies Diverged From Traditional Biologics?
Traditional biologics manufacturing relies on a centralized production model: large facilities producing substantial volumes of stable material distributed broadly to serve large patient populations, a model that scales efficiently as demand increases. Many advanced therapies cannot follow this model, because the material involved is either freshly manufactured for immediate patient use or carefully cryopreserved in ways that require close physical proximity to the point of care to preserve therapeutic viability — a constraint with no real equivalent in traditional biologics manufacturing.
This divergence has pushed the advanced therapies field toward genuinely different manufacturing architectures, including hub-and-spoke models that combine centralized processing steps with geographically distributed final manufacturing or formulation closer to treatment centers, and growing reliance on specialized contract manufacturing organizations that have built the proximity-dependent infrastructure traditional biologics manufacturers were never required to develop. Companies entering advanced therapy development benefit from recognizing early that this manufacturing divergence isn’t a temporary scaling challenge to be solved with more capital alone — it reflects a structurally different category of product requiring structurally different manufacturing strategy from the outset.
What Should Companies and Investors Understand About This Category’s Trajectory?
Given how quickly the advanced therapies category continues to expand both in approved-product count and in the range of modalities and indications under active development, treating “advanced therapies” as a single, static category risks missing meaningful differences in maturity, risk profile, and commercial trajectory across its constituent modalities. Cell therapy, particularly CAR-T in hematologic disease, has reached genuine commercial maturity. Gene editing remains the fastest-growing segment by trial volume but has a much shorter approval track record. mRNA-based therapeutics and engineered bacteriophage applications, while sharing the advanced therapies designation, sit earlier still in their respective development trajectories. Evaluating any specific advanced therapy program requires understanding not just which broad category it falls into, but where its specific modality actually sits on this continuum of scientific and regulatory maturity.